The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


News Update

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial

News Update
  ()
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. read more >

Analyst: Biotech Expecting a 'Catalyst-Rich' Second Half of the Year

Research Report
  ()
An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year. read more >

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue

  ()
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. read more >

Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'

Research Report
  ()
Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report. read more >

BioNTech Shares Gain 11% on Filing COVID-19 Vaccine Expanded Use Request to EMA in Children Ages 12 to 15

  ()
BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine. read more >

Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial

  ()
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer. read more >

ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50%

  ()
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. read more >

Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients

Research Report
  ()
The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report. read more >

Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial

  ()
Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study. read more >

Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors

  ()
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher for the day after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price. read more >

Is the Trend Turning for This Psychedelic Stock?

Contributed Opinion
  ()
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. read more >

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3

  ()
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. read more >

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio

Research Report
  ()
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. read more >

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial

  ()
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. read more >

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial

  ()
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. read more >

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'

Research Report
  ()
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." read more >

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue

Research Report
  ()
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. read more >

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine

  ()
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. read more >

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD

  ()
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. read more >
News Update

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF

News Update
  ()
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. read more >

Data from Humanigen's Phase 3 COVID-19 Trial Show 54% Increase in Survival Rates

  ()
Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumab™ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation. read more >

ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial

  ()
ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. read more >

Aptose Biosciences Shares Rise 55% on Q4 Financial Results and Promising Clinical Trials

  ()
Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers. read more >

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April

Research Report
  ()
Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report. read more >

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates

Contributed Opinion
  ()
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about. read more >
Showing Results: 1 to 25 of 104 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts